Loading…
Health economic evaluation in idiopathic pulmonary fibrosis in France
Background: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. To date, there is no specific cure for IPF, and only two treatments (pirfenidone and nintedanib) have marketing authorizations and recommendations in interna...
Saved in:
| Published in: | Current medical research and opinion 2018-10, Vol.34 (10), p.1731-1740 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c366t-3e54df3010fce535c69e13991815d545670fadeee3e181c8a37ca2ea8e0bda253 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c366t-3e54df3010fce535c69e13991815d545670fadeee3e181c8a37ca2ea8e0bda253 |
| container_end_page | 1740 |
| container_issue | 10 |
| container_start_page | 1731 |
| container_title | Current medical research and opinion |
| container_volume | 34 |
| creator | Porte, Fanny Cottin, Vincent Catella, Laura Luciani, Laura Le Lay, Katell Bénard, Stève |
| description | Background: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. To date, there is no specific cure for IPF, and only two treatments (pirfenidone and nintedanib) have marketing authorizations and recommendations in international and French guidelines.
Objectives: A cost-utility analysis (CUA) has been conducted to evaluate the efficiency of nintedanib, in comparison to all available alternatives, in a French setting using the official methodological guidelines.
Methods: A previously developed lifetime Markov model was adapted to the French setting by simulating the progression of IPF patients in terms of lung function decline, incidence of acute exacerbations, and death. Considering the effect of IPF on patients' quality-of-life, a CUA integrating quality adjusted life years (QALY) was chosen as the primary outcome measure in the main analysis. One-way, probabilistic, and scenario sensitivity analyses were performed to evaluate the robustness of the model.
Results: Treatment with nintedanib resulted in an estimated total cost of €76,414 (vs €82,665 for pirfenidone). In comparison with all other available options, nintedanib was predicted to provide the most QALY gained (3.34 vs 3.29). This analysis suggests that nintedanib has a 59.0% chance of being more effective than pirfenidone and s 77.3% chance of being cheaper than pirfenidone. Sensitivity analyses showed the results of the CUA to be robust.
Conclusions: In conclusion, this CUA has found that nintedanib appears to be a more cost-effective therapeutic option than pirfenidone in a French setting, due to fewer acute exacerbations and a better tolerability profile. |
| doi_str_mv | 10.1080/03007995.2018.1433143 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1991183874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1991183874</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-3e54df3010fce535c69e13991815d545670fadeee3e181c8a37ca2ea8e0bda253</originalsourceid><addsrcrecordid>eNp9kM9LwzAUgIMobk7_BGVHL51J07TJTRmbEwZe9Byy9IVF0qYmrbL_3pRNj0Iegfe-94MPoVuCFwRz_IApxpUQbJFjwhekoDTFGZqSoqJZwavqHE1HJhuhCbqK8QNjknMhLtEkF7TkouBTtNqAcv1-Dtq3vrF6Dl_KDaq3vp3b9GrrO9XvU6EbXONbFQ5zY3fBRxtHYB1Uq-EaXRjlItyc_hl6X6_elpts-_r8snzaZpqWZZ9RYEVtKCbYaGCU6VIAoUIQTljNClZW2KgaACiklOaKVlrloDjgXa1yRmfo_ji3C_5zgNjLxkYNzqkW_BAlSbMIp7wqEsqOqE63xgBGdsE26XxJsBwNyl-DcjQoTwZT391pxbBroP7r-lWWgMcjYFvjQ6O-fXC17NXB-WBGGzZK-v-OHwBlgBM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1991183874</pqid></control><display><type>article</type><title>Health economic evaluation in idiopathic pulmonary fibrosis in France</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Porte, Fanny ; Cottin, Vincent ; Catella, Laura ; Luciani, Laura ; Le Lay, Katell ; Bénard, Stève</creator><creatorcontrib>Porte, Fanny ; Cottin, Vincent ; Catella, Laura ; Luciani, Laura ; Le Lay, Katell ; Bénard, Stève</creatorcontrib><description>Background: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. To date, there is no specific cure for IPF, and only two treatments (pirfenidone and nintedanib) have marketing authorizations and recommendations in international and French guidelines.
Objectives: A cost-utility analysis (CUA) has been conducted to evaluate the efficiency of nintedanib, in comparison to all available alternatives, in a French setting using the official methodological guidelines.
Methods: A previously developed lifetime Markov model was adapted to the French setting by simulating the progression of IPF patients in terms of lung function decline, incidence of acute exacerbations, and death. Considering the effect of IPF on patients' quality-of-life, a CUA integrating quality adjusted life years (QALY) was chosen as the primary outcome measure in the main analysis. One-way, probabilistic, and scenario sensitivity analyses were performed to evaluate the robustness of the model.
Results: Treatment with nintedanib resulted in an estimated total cost of €76,414 (vs €82,665 for pirfenidone). In comparison with all other available options, nintedanib was predicted to provide the most QALY gained (3.34 vs 3.29). This analysis suggests that nintedanib has a 59.0% chance of being more effective than pirfenidone and s 77.3% chance of being cheaper than pirfenidone. Sensitivity analyses showed the results of the CUA to be robust.
Conclusions: In conclusion, this CUA has found that nintedanib appears to be a more cost-effective therapeutic option than pirfenidone in a French setting, due to fewer acute exacerbations and a better tolerability profile.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1080/03007995.2018.1433143</identifier><identifier>PMID: 29368948</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>cost-benefit analysis ; France ; Idiopathic pulmonary fibrosis ; nintedanib ; pirfenidone</subject><ispartof>Current medical research and opinion, 2018-10, Vol.34 (10), p.1731-1740</ispartof><rights>2018 Informa UK Limited, trading as Taylor & Francis Group 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-3e54df3010fce535c69e13991815d545670fadeee3e181c8a37ca2ea8e0bda253</citedby><cites>FETCH-LOGICAL-c366t-3e54df3010fce535c69e13991815d545670fadeee3e181c8a37ca2ea8e0bda253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29368948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Porte, Fanny</creatorcontrib><creatorcontrib>Cottin, Vincent</creatorcontrib><creatorcontrib>Catella, Laura</creatorcontrib><creatorcontrib>Luciani, Laura</creatorcontrib><creatorcontrib>Le Lay, Katell</creatorcontrib><creatorcontrib>Bénard, Stève</creatorcontrib><title>Health economic evaluation in idiopathic pulmonary fibrosis in France</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>Background: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. To date, there is no specific cure for IPF, and only two treatments (pirfenidone and nintedanib) have marketing authorizations and recommendations in international and French guidelines.
Objectives: A cost-utility analysis (CUA) has been conducted to evaluate the efficiency of nintedanib, in comparison to all available alternatives, in a French setting using the official methodological guidelines.
Methods: A previously developed lifetime Markov model was adapted to the French setting by simulating the progression of IPF patients in terms of lung function decline, incidence of acute exacerbations, and death. Considering the effect of IPF on patients' quality-of-life, a CUA integrating quality adjusted life years (QALY) was chosen as the primary outcome measure in the main analysis. One-way, probabilistic, and scenario sensitivity analyses were performed to evaluate the robustness of the model.
Results: Treatment with nintedanib resulted in an estimated total cost of €76,414 (vs €82,665 for pirfenidone). In comparison with all other available options, nintedanib was predicted to provide the most QALY gained (3.34 vs 3.29). This analysis suggests that nintedanib has a 59.0% chance of being more effective than pirfenidone and s 77.3% chance of being cheaper than pirfenidone. Sensitivity analyses showed the results of the CUA to be robust.
Conclusions: In conclusion, this CUA has found that nintedanib appears to be a more cost-effective therapeutic option than pirfenidone in a French setting, due to fewer acute exacerbations and a better tolerability profile.</description><subject>cost-benefit analysis</subject><subject>France</subject><subject>Idiopathic pulmonary fibrosis</subject><subject>nintedanib</subject><subject>pirfenidone</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kM9LwzAUgIMobk7_BGVHL51J07TJTRmbEwZe9Byy9IVF0qYmrbL_3pRNj0Iegfe-94MPoVuCFwRz_IApxpUQbJFjwhekoDTFGZqSoqJZwavqHE1HJhuhCbqK8QNjknMhLtEkF7TkouBTtNqAcv1-Dtq3vrF6Dl_KDaq3vp3b9GrrO9XvU6EbXONbFQ5zY3fBRxtHYB1Uq-EaXRjlItyc_hl6X6_elpts-_r8snzaZpqWZZ9RYEVtKCbYaGCU6VIAoUIQTljNClZW2KgaACiklOaKVlrloDjgXa1yRmfo_ji3C_5zgNjLxkYNzqkW_BAlSbMIp7wqEsqOqE63xgBGdsE26XxJsBwNyl-DcjQoTwZT391pxbBroP7r-lWWgMcjYFvjQ6O-fXC17NXB-WBGGzZK-v-OHwBlgBM</recordid><startdate>20181003</startdate><enddate>20181003</enddate><creator>Porte, Fanny</creator><creator>Cottin, Vincent</creator><creator>Catella, Laura</creator><creator>Luciani, Laura</creator><creator>Le Lay, Katell</creator><creator>Bénard, Stève</creator><general>Taylor & Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181003</creationdate><title>Health economic evaluation in idiopathic pulmonary fibrosis in France</title><author>Porte, Fanny ; Cottin, Vincent ; Catella, Laura ; Luciani, Laura ; Le Lay, Katell ; Bénard, Stève</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-3e54df3010fce535c69e13991815d545670fadeee3e181c8a37ca2ea8e0bda253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>cost-benefit analysis</topic><topic>France</topic><topic>Idiopathic pulmonary fibrosis</topic><topic>nintedanib</topic><topic>pirfenidone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Porte, Fanny</creatorcontrib><creatorcontrib>Cottin, Vincent</creatorcontrib><creatorcontrib>Catella, Laura</creatorcontrib><creatorcontrib>Luciani, Laura</creatorcontrib><creatorcontrib>Le Lay, Katell</creatorcontrib><creatorcontrib>Bénard, Stève</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Porte, Fanny</au><au>Cottin, Vincent</au><au>Catella, Laura</au><au>Luciani, Laura</au><au>Le Lay, Katell</au><au>Bénard, Stève</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Health economic evaluation in idiopathic pulmonary fibrosis in France</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2018-10-03</date><risdate>2018</risdate><volume>34</volume><issue>10</issue><spage>1731</spage><epage>1740</epage><pages>1731-1740</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Background: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. To date, there is no specific cure for IPF, and only two treatments (pirfenidone and nintedanib) have marketing authorizations and recommendations in international and French guidelines.
Objectives: A cost-utility analysis (CUA) has been conducted to evaluate the efficiency of nintedanib, in comparison to all available alternatives, in a French setting using the official methodological guidelines.
Methods: A previously developed lifetime Markov model was adapted to the French setting by simulating the progression of IPF patients in terms of lung function decline, incidence of acute exacerbations, and death. Considering the effect of IPF on patients' quality-of-life, a CUA integrating quality adjusted life years (QALY) was chosen as the primary outcome measure in the main analysis. One-way, probabilistic, and scenario sensitivity analyses were performed to evaluate the robustness of the model.
Results: Treatment with nintedanib resulted in an estimated total cost of €76,414 (vs €82,665 for pirfenidone). In comparison with all other available options, nintedanib was predicted to provide the most QALY gained (3.34 vs 3.29). This analysis suggests that nintedanib has a 59.0% chance of being more effective than pirfenidone and s 77.3% chance of being cheaper than pirfenidone. Sensitivity analyses showed the results of the CUA to be robust.
Conclusions: In conclusion, this CUA has found that nintedanib appears to be a more cost-effective therapeutic option than pirfenidone in a French setting, due to fewer acute exacerbations and a better tolerability profile.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>29368948</pmid><doi>10.1080/03007995.2018.1433143</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 2018-10, Vol.34 (10), p.1731-1740 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1991183874 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | cost-benefit analysis France Idiopathic pulmonary fibrosis nintedanib pirfenidone |
| title | Health economic evaluation in idiopathic pulmonary fibrosis in France |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T22%3A40%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Health%20economic%20evaluation%20in%20idiopathic%20pulmonary%20fibrosis%20in%20France&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Porte,%20Fanny&rft.date=2018-10-03&rft.volume=34&rft.issue=10&rft.spage=1731&rft.epage=1740&rft.pages=1731-1740&rft.issn=0300-7995&rft.eissn=1473-4877&rft_id=info:doi/10.1080/03007995.2018.1433143&rft_dat=%3Cproquest_cross%3E1991183874%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-3e54df3010fce535c69e13991815d545670fadeee3e181c8a37ca2ea8e0bda253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1991183874&rft_id=info:pmid/29368948&rfr_iscdi=true |